Related Experiment Video
Updated: Aug 18, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Therapeutic options in advanced cutaneous T cell lymphomas: a role for interferon alfa-2a (Roferon-A)
Abstract:
Interferon alfa-2a (Roferon-A) was given to 20 patients with advanced cutaneous T cell lymphomas, all of whom were heavily pretreated. Objective responses were seen in nine of the 20 patients, including seven partial and two complete responses. The median response duration was 5.5 months, with three of the responses lasting 2 or more years. Toxicity was moderate but was alleviated by dose reductions. These results demonstrate that Roferon-A is highly effective in the treatment of advanced refractory cutaneous T cell lymphomas. The role of this treatment in earlier stages of disease and in combination with other standard forms of therapy needs to be evaluated.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Inhibitors of Viral Protein Synthesis

